###begin article-title 0
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
CTLA-4 +49A/G and CT60 gene polymorphisms in primary Sjogren syndrome
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 135 142 135 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 386 393 386 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 517 524 517 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 758 765 758 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 866 868 866 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 960 967 960 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 1037 1039 1037 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1060 1062 1060 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1101 1108 1101 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 1209 1211 1209 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1260 1267 1260 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 1444 1446 1444 1446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1481 1488 1481 1488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 1612 1619 1612 1619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 1942 1949 1942 1949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 579 587 <span type="species:ncbi:9606">patients</span>
###xml 711 719 <span type="species:ncbi:9606">patients</span>
###xml 816 824 <span type="species:ncbi:9606">patients</span>
###xml 1027 1035 <span type="species:ncbi:9606">patients</span>
###xml 1159 1167 <span type="species:ncbi:9606">patients</span>
###xml 1296 1304 <span type="species:ncbi:9606">patients</span>
###xml 1406 1414 <span type="species:ncbi:9606">patients</span>
###xml 1842 1850 <span type="species:ncbi:9606">patients</span>
CTLA-4 encodes cytotoxic T lymphocyte-associated antigen-4, a cell-surface molecule providing a negative signal for T-cell activation. CTLA-4 gene polymorphisms have been widely studied in connection with genetic susceptibility to various autoimmune diseases, but studies have led to contradictory results in different populations. This case-control study sought to investigate whether CTLA-4 CT60 and/or +49A/G polymorphisms were involved in the genetic predisposition to primary Sjogren syndrome (pSS). We analysed CTLA-4 CT60 and +49A/G polymorphisms in a first cohort of 142 patients with pSS (cohort 1) and 241 controls, all of Caucasian origin. A replication study was performed on a second cohort of 139 patients with pSS (cohort 2). In cohort 1, the CTLA-4 +49A/G*A allele was found on 73% of chromosomes in patients with pSS, compared with 66% in controls (p = 0.036; odds ratio (OR) 1.41, 95% confidence interval (CI) 1.02 to 1.95). No difference in CTLA-4 CT60 allelic or genotypic distribution was observed between patients (n = 142) and controls (n = 241). In the replication cohort, the CTLA-4 +49A/G*A allele was found on 62% of chromosomes in patients with pSS, compared with 66% in controls (p = 0.30; OR 0.85, 95% CI 0.63 to 1.16). Thus, the CTLA-4 +49A/G*A allele excess among patients from cohort 1 was counterbalanced by its under-representation in cohort 2. When the results from the patients in both cohorts were pooled (n = 281), there was no difference in CTLA-4 +49A/G allelic or genotypic distribution in comparison with controls. Our results demonstrate a lack of association between CTLA-4 CT60 or +49A/G polymorphisms and pSS. Premature conclusions might have been made if a replication study had not been performed. These results illustrate the importance of case-control studies performed on a large number of patients. In fact, sampling bias may account for some contradictory results previously reported for CTLA-4 association studies in autoimmune diseases.
###end p 2
###begin p 3
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
See related letter by Lester et al.,  and related letter by Miceli-Richard et al.,
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4</italic>
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
Polymorphisms in CTLA-4, the gene encoding cytotoxic T lymphocyte-associated antigen-4, have been widely studied in connection with genetic susceptibility to various autoimmune diseases [1], but studies have led to contradictory results in different populations.
###end p 5
###begin p 6
###xml 6 13 6 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 492 499 492 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 609 610 609 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 714 715 714 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Among CTLA-4 gene polymorphisms, a G to A transition at position 49 (+49A/G) of exon 1 leads to an alanine to threonine amino acid substitution at codon 17 in the leader peptide (A17T), and a C to T transition at position 60 (CT60) is located within the 3'-untranslated region [2]. The G allele of +49A/G has been associated with a predisposition to many autoimmune diseases (reviewed in [1]). Both polymorphisms are in linkage disequilibrium, which warrants haplotype analysis in studies of CTLA-4 polymorphisms. The CT60 G allele has been reported to increase susceptibility to several autoimmune diseases [2], and a functional approach provided evidence for lower mRNA levels associated with the CT60 G allele [2].
###end p 6
###begin p 7
###xml 84 91 84 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 118 125 118 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
Downie-Doyle and colleagues have recently reported a significant association of the CTLA-4 +49A/G*A allele and of the CTLA-4 +49A/G*A allele carrier haplotypes with primary Sjogren syndrome (pSS), especially in patients with anti-SSA or anti-SSB antibodies, in a study including 111 Australian patients with pSS and 156 controls [3].
###end p 7
###begin p 8
###xml 78 85 78 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
The aim of our study was to investigate in a large case-control study whether CTLA-4 CT60 and/or +49A/G SNPs were involved in genetic predisposition to pSS in French patients.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 10
###begin p 11
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 294 301 294 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 411 418 411 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
###xml 537 545 <span type="species:ncbi:9606">patients</span>
###xml 635 643 <span type="species:ncbi:9606">patients</span>
###xml 747 755 <span type="species:ncbi:9606">patients</span>
A first cohort of 142 unrelated patients with pSS diagnosed in accordance with the European American consensus group criteria [4] (37% without autoantibodies, 30% with anti-SSA antibodies only, and 33% with both anti-SSA and anti-SSB antibodies) and 241 healthy blood donors were genotyped for CTLA-4 CT60 and +49A/G polymorphisms. A second independent cohort of 139 patients with pSS was further genotyped for CTLA-4 +49A/G polymorphisms in a replication study. The geographical origin and the clinico-biological characteristics of the patients in this second cohort were the same as those in the first. In this second cohort, 27% of patients were anti-SSA and anti-SSB negative, 35% had anti-SSA only and 38% had both anti-SSA and anti-SSB. All patients and controls were Caucasians and provided informed consent.
###end p 11
###begin title 12
Genotyping
###end title 12
###begin p 13
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 188 191 188 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bbv</italic>
###xml 206 209 206 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nla</italic>
After the isolation of genomic DNA from peripheral blood mononuclear cells, CTLA-4 CT60 and +49A/G polymorphisms were genotyped by restriction fragment length polymorphism with the use of BbvI (+49A/G) and NlaIII (CT60).
###end p 13
###begin title 14
Statistical analysis
###end title 14
###begin p 15
###xml 37 44 37 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 142 144 140 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 205 212 203 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 322 324 320 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Allelic and genotypic frequencies of CTLA-4 CT60 and +49A/G polymorphisms were compared between patients and controls by using a two-sided chi2 test. All genotyped SNPs were in Hardy-Weinberg equilibrium. CTLA-4 (+49A/G or CT60) haplotypes, constructed with the PHASE program, were also examined for association with pSS. P < 0.05 was considered significant.
###end p 15
###begin title 16
Results
###end title 16
###begin p 17
###xml 62 69 62 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 179 181 179 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 294 301 294 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 449 456 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 526 528 526 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 549 551 549 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 559 566 559 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 619 626 619 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 848 850 848 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
###xml 516 524 <span type="species:ncbi:9606">patients</span>
###xml 655 663 <span type="species:ncbi:9606">patients</span>
###xml 838 846 <span type="species:ncbi:9606">patients</span>
In the first cohort of patients with pSS, the A allele of the CTLA-4 +49A/G polymorphism was found on 73% of chromosomes in patients with pSS, in comparison with 66% in controls (p = 0.036, odds ratio (OR) 1.41, 95% confidence interval (CI) 1.02 to 1.95; Table 1). No significant difference in CTLA-4 +49A/G*A allele frequencies was observed among subgroups of patients according to their anti-SSB and/or anti-SSA status (Table 1). No difference in CTLA-4 CT60 allelic or genotypic distribution was observed between patients (n = 142) and controls (n = 241). CTLA-4 (+49A/G or CT60) haplotype distribution mirrored the CTLA-4 +49A/G*A allele excess among patients with pSS (A/A 48%, A/G 26%, G/G 26%, G/A 0.4%; in comparison with A/A 45%, A/G 21%, G/G 34% among controls), leading to an excess of +49A/G*A allele carrier haplotypes among patients (p = 0.03, OR 1.41, 95% CI 1.02 to 1.95).
###end p 17
###begin p 18
###xml 24 31 24 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 56 63 <span type="species:ncbi:9606">patient</span>
Allellic frequencies of CTLA-4 49A/G polymorphism among patient controls
###end p 18
###begin p 19
Numbers in parentheses are percentages. pSS, primary Sjogren syndrome; Ac+, presence of anti SSB and/or anti-SSA; Ac0, absence of anti-SSA or anti-SSB antibody; CI, confidence interval; NS, not significant.
###end p 19
###begin p 20
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 168 175 168 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 270 277 270 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 294 295 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 415 422 415 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 523 525 523 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 569 570 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 583 590 583 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 793 795 793 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 830 837 830 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 920 922 920 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 965 966 965 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1068 1075 1068 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 1214 1216 1214 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 369 377 <span type="species:ncbi:9606">patients</span>
###xml 473 481 <span type="species:ncbi:9606">patients</span>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
###xml 755 763 <span type="species:ncbi:9606">patients</span>
###xml 990 998 <span type="species:ncbi:9606">patients</span>
To avoid the possibility of a false positive association of CTLA-4 +49A/G*A with pSS as a result of the somewhat small sample size of our first cohort, and because the CTLA-4 +49A/G*A allele has been only marginally associated with autoimmune diseases compared with the CTLA-4 +49A/G*G allele [1], we performed a replication study on a second independent cohort of 139 patients with pSS. In this second cohort, the CTLA-4 +49A/G*A allele was found on 62% of chromosomes in patients with pSS, compared with 66% in controls (p = 0.30; OR 0.85, 95% CI 0.63 to 1.16; Table 1). Thus, the CTLA-4 +49A/G*A allele excess among patients with pSS from the first cohort was counterbalanced by its under-representation in the second cohort. When the results from the patients in both cohorts were pooled (n = 281), there was no difference in CTLA-4 +49A/G polymorphism allelic or genotypic distribution in comparison with controls (p = 0.53, OR 1.09, 95% CI 0.84 to 1.4; Table 1). The sex ratios among patients (0.97) and controls (0.06) were different. We therefore investigated CTLA-4 +49A/G polymorphism genotypic distribution among males and females in the control group and found that it was not statistically different (p = 0.1), thus excluding any possible gender effect.
###end p 20
###begin p 21
###xml 64 71 64 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
Our results therefore demonstrate a lack of association between CTLA-4 CT60 or +49A/G polymorphisms and pSS among Caucasians.
###end p 21
###begin title 22
Discussion
###end title 22
###begin p 23
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 312 319 312 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 394 401 394 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 494 501 494 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 511 518 511 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 577 584 577 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
The results from our first cohort were very close to those from the study of Downie-Doyle and colleagues [3], with a significant association of pSS with the +49A/G*A allele and with the +49A/G*A allele carriers haplotypes. The association observed in the first cohort, of two haplotypes bearing the same allele (CTLA-4 +49A/G*A), was actually more probably due to the statistical weight of the CTLA-4 +49A/G*A allele than to a true functional effect of two different haplotypes, bearing either CTLA-4 CT60*C or CTLA-4 CT60*T alleles, each having opposite functional effects on CTLA-4 mRNA expression [2].
###end p 23
###begin p 24
###xml 61 68 61 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 213 220 213 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 579 580 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 658 664 658 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4</italic>
###xml 703 704 703 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 705 706 705 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
###xml 394 402 <span type="species:ncbi:9606">patients</span>
###xml 526 534 <span type="species:ncbi:9606">patients</span>
In fact, our results suggest a false positive association of CTLA-4 +49A/G*A allele with pSS in the first cohort of patients. When data were pooled (cohorts 1 and 2), no significant association was found with the CTLA-4 +49A/G polymorphism in our Caucasian population of patients with pSS. This was not the consequence of different origin or different clinico-biological characteristics of the patients from the two cohorts and could only be the result of a sampling bias. Indeed, the findings observed in our first cohort of patients, as those from Downie-Doyle and colleagues [3], were unexpected because there are only rare examples of association of the CTLA-4A/G*A allele with autoimmune diseases [5-7]. Consequently, we might have made premature conclusions if a replication study had not been performed.
###end p 24
###begin title 25
Conclusion
###end title 25
###begin p 26
###xml 204 211 204 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Our study illustrates the necessity to include a large number of patients in genetic case-control studies. In fact, sampling bias may partly account for some contradictory results previously reported for CTLA-4 association studies in autoimmune diseases.
###end p 26
###begin title 27
Abbreviations
###end title 27
###begin p 28
CI = confidence interval; CTLA-4 = cytotoxic T lymphocyte-associated antigen-4; OR = odds ratio; pSS = primary Sjogren syndrome; SNP = single nucleotide polymorphism.
###end p 28
###begin title 29
Competing interests
###end title 29
###begin p 30
The authors declare that they have no competing interests.
###end p 30
###begin title 31
Authors' contributions
###end title 31
###begin p 32
JEG contributed to the study design, performed the statistical analysis and drafted the manuscript. PL and DC supervised genotyping and contributed to DNA samples collection. MA and CC performed genotyping. NC performed PHASE analyses. EH, XP, and JS contributed to DNA samples collection. XM and CMR supervised the study design and gave valuable advice to JEG and PL. All authors read and approved the final manuscript.
###end p 32
###begin title 33
Acknowledgements
###end title 33
###begin p 34
This study was supported by Reseau de recherche clinique INSERM.
###end p 34
###begin article-title 35
CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity?
###end article-title 35
###begin article-title 36
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
###end article-title 36
###begin article-title 37
Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren's syndrome
###end article-title 37
###begin article-title 38
Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group
###end article-title 38
###begin article-title 39
CTLA-4 gene polymorphism is associated with predisposition to coeliac disease
###end article-title 39
###begin article-title 40
The CTLA4+49A/G and CT60 polymorphisms and chronic inflammatory arthropathies in Northern Ireland
###end article-title 40
###begin article-title 41
###xml 38 46 <span type="species:ncbi:9606">patients</span>
CTLA-4 gene polymorphisms in Tunisian patients with Graves' disease
###end article-title 41

